Since CD19 has been expressed in most B-cell NHL patients, denintuzumabmafodotin (SGN-CD19A) can be a novel antibody-drug conjugate consisting of a humanized anti-CD19 mAb attached to the microtubule-disrupting agent monomethyla-uristatin F (MMAF) through a maleimidocaproyl linker.

CD19 monoclonal antibodies work by targeting the CD19 protein that is present on the surface of pre-B and mature B lymphocytes and overexpressed in several different cancers, including CD19-positive B-cell leukemias or lymphomas.

Objective: This article summarizes the background, clinical trials, and place in therapy for the first two anti-CD19 monoclonal antibodies that have been recently FDA approved for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

Antibodies that detect CD19 can be used in several scientific applications, including Flow Cytometry, Immunohistochemistry, Western Blot, Immunocytochemistry and ELISA. These antibodies target CD19 in Human, Mouse, Rat, Non-human primate and Chimpanzee samples. Our CD19 monoclonal,...

CD19 (Intracellular Domain) (D4V4B) XP ® Rabbit mAb recognizes endogenous levels of total CD19 protein. The antigen sequence used to produce this antibody shares 100% sequence homology with the species listed here, but reactivity has not been tested or …

At present, four classes of drugs have been designed to target CD19: unconjugated monoclonal antibodies (mAb), antibody-drug conjugates (ADC) and molecules that specifically recruit T-cells, including bispecific T cell engagers (BiTE) and chimeric-antigen receptors (CAR).

Nov 6, 2021 · Blinatumomab, tafasitamab and loncastuximab tesirine are novel monoclonal antibody-based treatments that target CD19, a cell surface protein that is present throughout the B-cell maturation process, and consequently is an important therapeutic target in patients with B-cell malignancies.

CD19 is a biomarker for normal and neoplastic B cells, as well as follicular dendritic cells. CD19 is critically involved in establishing intrinsic B cell signaling thresholds through modulating both B cell receptor-dependent and independent signaling.

Feb 27, 2025 · In this issue of Blood, Koh et al 1 investigate how concurrent treatment with an anti-CD19 monoclonal antibody (mAb) can boost the antitumor efficacy of chimeric antigen receptor (CAR)–modified immune effector cells, specifically FMC63 CD19-targeted CAR natural killer and CAR T cells.

Nov 16, 2008 · XmAb®5574 is an Fc engineered humanized monoclonal antibody (mAb) that binds to the human cell surface antigen CD19 and demonstrates anti-proliferative activity against CD19-positive (CD19+) cell lines.